Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004
30 Avril 2004 - 11:30PM
PR Newswire (US)
Allos to Discuss ODAC Panel Recommendation on Monday May 3, 2004
WESTMINSTER, Colo., April 30 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. will hold a conference call Monday afternoon to
discuss the outcome of the Oncologic Drugs Advisory Committee
(ODAC) meeting on the company's investigational radiation
sensitizer, RSR13 (efaproxiral). Investors and media are invited to
participate. Time: 5:15 PM EDT* Date: Monday, May 3, 2004 Location:
The Hilton Hotel, Gaithersburg, MD Dial-in: (800) 915-4836 / (973)
317-5319 international Webcast: http://www.allos.com/ (homepage and
investor relations section) *If the ODAC meeting continues past
5:15 PM, the start of the conference call will be delayed until
after the meeting's conclusion. Interested parties unable to
participate in the live conference call may access a recorded
rebroadcast by dialing 1-800-428-6051, or +1-973-709-2089 for
international callers; the conference ID number is 353015. The
replay will be available from 7:00 p.m. ET on Monday, May 3, 2004
until 11:59 PM ET on May 10, 2004. In addition, the webcast will be
archived for on-demand listening for 30 days at
http://www.allos.com/. About Allos Therapeutics, Inc. Allos
Therapeutics, Inc. is a biopharmaceutical company focused on
developing and commercializing innovative drugs for improving
cancer treatments. The company's lead clinical candidate, RSR13
(efaproxiral), is a synthetic small molecule that has the potential
to sensitize hypoxic (oxygen deprived) tumor tissues and enhance
the efficacy of standard radiation therapy. In addition, Allos is
developing PDX, an injectable small molecule chemotherapeutic agent
that has a superior potency and toxicity profile relative to
methotrexate and other dihydrofolate reductase, or DHFR,
inhibitors. For more information, please visit the company's web
site at: http://www.allos.com/. DATASOURCE: Allos Therapeutics,
Inc. CONTACT: Monique M. Greer VP, Corporate Communications and
Investor Relations of Allos Therapeutics, Inc., +1-970-215-3260, ;
or Media, Fern Lazar, +1-917-362-2264, or Amy Raskopf,
+1-917-673-5775, both of Lazar Partners Limited, +1-212-867-1762,
for Allos Therapeutics, Inc. Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics (MM)